The effects of cranberry juice on serum glucose, apoB, apoA-I, Lp(a), and paraoxonase-1 activity in type 2 diabetic male patients

Journal of Research in Medical Sciences

Volumn 17, Issue 4, 2012, Pages 355-360

  Shidfar, Farzad ^a   Heydari, Iraj ^b   Hajimiresmaiel, Seyed Javad ^c   Hosseini, Sharieh ^c   Shidfar, Shahrzad ^d   Amiri, Fariba ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Endocrine Research Center   (Iran)

^c ISLAMIC AZAD UNIVERSITY   (Iran)

^d UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

Apo B; apoA 1; Cranberry; Glucose; Lp(a); Paraoxonase 1; Type 2 diabetes

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ARYLDIALKYLPHOSPHATASE 1; GLUCOSE; LIPOPROTEIN A;

ADULT; ARTICLE; CALORIC INTAKE; CARDIOVASCULAR RISK; COLORIMETRY; CONTROLLED STUDY; CRANBERRY JUICE; DOUBLE BLIND PROCEDURE; ENZYME ACTIVITY; FOOD INTAKE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; TURBIDIMETRY;

EID: 84861612429     PISSN: 17351995     EISSN: 17357136     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Hadaegh F, Fahimfar N, Khalili D, Sheikholeslami F, Azizi F. New and known type2 diabetes as coronary heart disease equivalent: Results from 7.6 year follow up in a middle east population. Cardiovasc Diabetol 2010;9:84.
2. Harati H, Hadaegh F, Saadat N, Azizi F. Population-based incidence of Type 2 diabetes and its associated risk factors: Results from a six-year cohort study in Iran. BMC Public Health 2009;9:186.
3. Dahlen EM, Lanne T, Engvall J, Lindstrom T, Grodzinsky E, Nystrom FH. Carotid intima-media thickness and apolipoprotein B/apolipoprotein A-I ratio in middle-aged patients with Type2 diabetes. Diabet Med 2009;26:384-90.
4. Harder H, Dinesen B, Astrup A. The effect of a rapid weight loss on lipid profile and glycemic control in obese type 2 diabetic patients. Int J Obes Relat Metab Disord 2004;28:180-2.
5. Williams K, Tchernof A, Hunt KJ, Wagenknecht LE, Haffner SM, Sniderman AD. Diabetes, abdominal adiposity and atherogenic dyslipoproteinemia in women compared with men. Diabetes 2008;57:3289-96.
6. Kastelein JP, van der Steeg WA, Holme I, Gaffney M, Cater NB, Barter P, et al. Lipids, apoproteins and their ratios in relation to cardiovascular events with statin treatment. Circulation 2008;117:3002-9.
7. Charton-Menyes V, Betteridge DJ, Colhoun H, Fuller J, France M, Hitman GA, et al. Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: The Collaborative Atrovastatin Diabetes Study (CARDS). Diabetologia 2009;52:218-25.
8. Sierra-Johnson J, Fisher RM, Romero-Corral A, Somers VK, Lopes-Jimenes F, Ohrvik J, et al. Concentration of apolipoprotein B is comparable with the apolipoprotein B/ apolipoprotein A-I in predicting coronary heart disease mortality: Findings from a multi-ethnic US population. Eur Heart J 2009;30:710-7.
9. Thompson A, Danesh J. Association between apolipoprotein B, apolipoprotein A-I, the apolipoprotein B/A-I ratio and coronary heart disease: A literature-based meta-analysis of prospective studies. J Intern Med 2006;259:481-92.
10. Canoui-Poitrine F, Luc G, Bard JM, Ferrieres J, Yarnell J, Arveiler D, et al. Relative contribution of lipids and apolipoproteins to incident coronary heart disease and ischemic stroke: The PRIME study. Cerebrovasc Dis 2010;30:252-9.
11. Mora S, Kamstrup PR, Rifai N, Nordestgaad BG, Buring JE, Ridker PM. Lipoprotein (a) and risk of type 2 diabetes. Clin Chem 2010;56:1257-60.
12. Nakhjavani M, Morteza A, Esteghamati A, Khalilzadeh O, Zandieh A, Safari R. Serum lipoprotein (a) levels are greater in female than male patients with type-2 diabetes. Lipids 2011;46:349-56.
13. Li C, Gu Q. Protective effect of paraoxonase-1 of high-density lipoprotein in type 2 diubetic patients with hephropathy. Nephrology (Carlton) 2009;14:514-20.
14. Connelly PW, Zinman B, Maguire GF, Mamakeesick M, Harris SB, Hegele RA. Association of the novel cardiovascular risk factors paraoxonase-1 and cystatin C in type2 diabetes. J lipid Res 2009;50:1216-22.
15. Getz GS, Reardon CA. Paraoxonase, a cardioprotective enzyme: Continuing issues. Curr Opin Lipidol 2004;15:261-7.
16. Mackness B, Mackness M. Anti-inflammatory properties of paraoxonase-1 in atherosclerosis. Adv Exp Med Biol 2010;660:143-51.
17. Jornayvaz FR, Brulhart-Meynet MC, James Rw. Myeloperoxidase and paraoxonase-1 in type 2 diabetic patients. Nutr Metab Cardiovasc Dis 2009;19:613-9.
18. Poh R, Muniandy S. Paraoxonase-1 activity as a predictor of cardiovascular disease in type 2 diabetes. Southeast Asian J Trop Med Public Health 2010;41:1231-46.
19. Jayakumari N, Thejaseebai G. High prevalence of low serum paraoxonase -1 in subjects with coronary artery disease. J Clin Biochem Nutr 2009;45:278-84.
20. Lee TI, Chan Yc, Lin CW, Lee WJ, Sheu WH. Effect of cranberry extracts on lipid profiles in subjects with Type 2 diabetes. Diabet Med 2008;25:1473-7.
21. Vinson JA, Su X, Zubik L, Bose P. Phenol antioxidant quantity and quality in foods: Fruits. J Agric Food Chem 2001;49:5315-21.
22. McKay Dl, Blumberg JB. Cranberries (Vaccinium macrocarpon) and cardiovascular disease risk factors. Nutr Rev 2007;65:490-502.
23. Rahbar M, Diba K. In vitro activity of cranberry extract against etiological agents of urinary tract infections. Afr J Pharm Pharmacol 2010;4:286-8.
24. Kim MJ, Jung HN, Nam Kim KN, Kwak HK. Effects of cranberry powder on serum lipid profiles and biomarkers of oxidative stress in rats fed an atherogenic diet. Nutr Res Practice 2008;2:158-64.
25. Wilson T, Singh AP, Vorsa N, Goettl CD, Kittleson KM, Roe CM, et al. Human glycemic response and phenolic content of unsweetened cranberry juice. J Med Food 2008;11:46-54.
26. Neto CC. Cranberry and blueberry: Evidence for protective effects against cancer and vascular diseases. Mol Nutr Food Res 2007;51:652-64.
27. Ruel G, Pomerleau S, Couture P, Lemieux S, Lamarche B, Couillard C. Favourable impact of low-calorie cranberry juice consumption on plasma HDL-Cholesterol concentrations in men. Br J Nutr 2006;96:357-64.
28. Craig CL, Marshall Al, Sjostrom M, Bauman AE, Booth ML, Ainsworft BE, et al. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sport Exerc 2003;35:1381-95.
29. Azadbakht L, Surkan PJ, Esmaillzadeh A, Willett WC. The dietary approaches to stop hypertension eating plan affects C-reactive protein, coagulation abnormalities, and hepatic function tests among type 2 diabetic patients. J Nutr 2011;141:1083-8.
30. Hinderliter AL, Babyak MA, Sherwood A, Blumenthal JA. The DASH diet and insulin sensitivity. Curr Hypertens Rep 2011; 13:67-73.
31. Azadbakht L, Fard NR, Karimi M, Baghaei MH, Surkan PJ, Rahimi M, et al. Effects of the dietary approaches to stop hypertension(DASH) eating plan on cardiovascular risks among type 2 diabetes patients: A randomized crossover clinical trial. Diabetes Care 2011;34:55-7.
32. Gan KN, Smolen A, Eckerson HW, La Du BN. Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab Dispos 1991;19:100-6.
33. Wilson T, Meyers SL, Singh AP, Limburg PJ, Vorsa N. Favorable glycemic response of type 2 diabetics to low-calorie cranberry juice. J Food Sci 2008;73:241-5.
34. Vinson JA, Bose P, Proch J, AL Kharrat H, Samman N. Cranberries and cranberry products: Powerful in vitro, ex vivo and in vivo sources of antioxidants. J Agric Food Chem 2008;56:5884-91.
35. Ruel G, Pomerleau S, Couture P, Lamarche B, Couillard C. Changes in plasma antioxidant capacity and oxidized low-density lipoprotein levels in men after short-term CJ consumption. Metabolism 2005;54:856-61.
36. Chambers BK, Camire EM. Can cranberry supplementation benefit adults with type 2 diabetes? Diabetes Care 2003;26:2695-6.
37. Pinto Mda S, Ghaedian R, Shinde R, Shetty K. Potential of cranberry powder for management of hyperglycemia using in vitro models. J Med Food 2010;13:1036-44.
38. Apostolidis E, Kwon YI, Shetty K. Potential of cranberry-based herbal synergies for diabetes and hypertension management. Asia Pac J Clin Nutr 2006;15:433-41.
39. Kahlon TS, Smith GE. In vitro binding of bile acids by blueberries, plums, prunes, strawberries, cherries, cranberries and apples. Food Chem 2007;100:1182-7.
40. Kalgaonkar S, Gross HB, Yokoyama W, Keen CL. Effects of a flavonol-rich diet on select cardiovascular parameters in a Golden Syrian hamster model. J Med Food 2010;13:108-15.
41. Francis GA. High density lipoprotein oxidation: In vitro susceptibility and potential in vivo consequences. Biochim Biophys Acta 2000;1483:217-35.
42. Singaraja RR, Fievet C, Castro G. Increased ABCA1 activity protects against atherosclerosis. J Clin Invest 2002;110:35-42.
43. Shidfar F, Froghifar N, Vafa MR, Rjab A, Hosseini S, Shidfar S, et al. The effects of tomato consumption on serum glucose, apolipoprotein B, apolipoprotein A-I, homocysteine and blood pressure in type 2 diabetic patients. Int J Food Sci Nutr 2001;62:289-94.
44. Shakouri Mahmoudabadi MM, Djalali M, Djazayery SA, Keshavarz SA, Eshraghian MR, Saboor-Yaraghi A, et al. J Res Med Sci 2011;16:361-7.
45. Stefanovic A, Kotur-stevuljevic J, Spasic C, Vekic J, Zeljkovic A, Spasojevic-Kalimanovska B, et al. HDL2 particles are associated with hyperglycaemia, lower PON1 activity and oxidative stress in type 2 diabetes mellitus. Clin Biochem 2010;43:1230-5.
46. Lu C, Gao Y, Zhou H, Tian H. The relationship between PON1 activity as well as oxLDL levels and coronary artery lesions in CHD patients with diabetes mellitus or impaired fasting glucose. Coron Artery Dis 2008;19:565-73.